Project information
Novel therapeutic options for venetoclax-resistant AML cells
(VeneresistAML)
- Project Identification
- MUNI/IGA/1198/2021
- Project Period
- 1/2022 - 12/2022
- Investor / Pogramme / Project type
-
Masaryk University
- Internal grant agency MU
- MU Faculty or unit
- Faculty of Science
Acute myeloid leukemia (AML) is a heterogeneous malignant disease affecting the hematopoietic precursors in the bone marrow. Despite promising outcomes of Venetoclax treatment in clinical studies, many cases were described in patients with an outgrowth of resistant subclones. Understanding the venetoclax-resistance mechanisms and detecting the major determinants could reveal previously unrecognized novel perspectives for therapeutic strategies to improve patients’ outcomes.